Symbols / LAB Stock $0.98 -0.39% Standard BioTools Inc.

Healthcare • Medical Devices • United States • NMS
LAB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Dr. Michael Egholm Ph.D.
Exch · Country NMS · United States
Market Cap 380.69M
Enterprise Value 225.13M
Income -58.83M
Sales 85.33M
FCF (ttm) -171.83M
Book/sh 1.10
Cash/sh 0.48
Employees 385
Insider 10d
IPO Feb 10, 2011
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E
Forward P/E -32.51
PEG
P/S 4.46
P/B 0.89
P/C
EV/EBITDA -2.73
EV/Sales 2.64
Quick Ratio 1.86
Current Ratio 4.19
Debt/Eq 7.27
LT Debt/Eq
EPS (ttm) -0.15
EPS next Y -0.03
EPS Growth
Revenue Growth -4.00%
EPS Gr Q/Q
Rev Gr Q/Q
Earnings (next) 2026-05-05
Earnings (prior) 2026-05-05
ROA -9.88%
ROE -13.13%
ROIC
Gross Margin 49.86%
Oper. Margin -92.14%
Profit Margin -87.77%
Shs Outstand 390.37M
Shs Float 216.47M
Insider Own 1.50%
Instit Own 76.89%
Short Float 3.59%
Short Ratio 3.20
Short Interest 8.48M
52W High 1.72
vs 52W High -43.30%
52W Low 0.87
vs 52W Low 12.09%
Beta 1.31
Impl. Vol. 28.80%
Rel Volume 0.51
Avg Volume 2.55M
Volume 1.29M
Target (mean) $1.55
Tgt Median $1.55
Tgt Low $1.35
Tgt High $1.75
# Analysts 2
Recom None
Prev Close $0.98
Price $0.98
Change -0.39%
About

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.98
Low
$1.35
High
$1.75
Mean
$1.55

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-05 main TD Cowen Hold → Hold $1
2025-02-27 down Keybanc Overweight → Sector Weight
2024-10-31 main TD Cowen Buy → Buy $3
2024-08-01 main TD Cowen Buy → Buy $3
2024-04-16 init TD Cowen — → Buy $4
2024-04-04 init Jefferies — → Buy $3
2023-07-12 init Keybanc — → Overweight $4
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-06 KIM HANJOON ALEX Chief Financial Officer 70,183
2026-04-06 EGHOLM MICHAEL Chief Executive Officer 196,513
2026-03-20 KIM HANJOON ALEX Chief Financial Officer 323,173 $0.00 $0
2026-03-20 EGHOLM MICHAEL Chief Executive Officer 1,042,373 $0.00 $0
2026-03-20 MACKAY SEAN Officer 272,107 $0.00 $0
2026-02-26 CAREY THOMAS D Director 51,282 $1.17 $60,000
2026-02-26 COX TROY M Director 57,264 $1.17 $66,999
2026-02-26 CASDIN ELI Director and Beneficial Owner of more than 10% of a Class of Security 52,991 $1.17 $61,999
2025-12-04 CASDIN PARTNERS MASTER FUND, L.P. Beneficial Owner of more than 10% of a Class of Security 350,000 $1.42 $502,570
2025-11-25 CASDIN PARTNERS MASTER FUND, L.P. Beneficial Owner of more than 10% of a Class of Security 7,700,000 $1.30 $10,053,280
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
85.33
-6.24%
91.01
-14.42%
106.34
+8.57%
97.95
Operating Revenue
85.33
-6.24%
91.01
-14.42%
106.34
+10.58%
96.17
Cost Of Revenue
42.79
-7.23%
46.12
-17.47%
55.89
-8.22%
60.90
Reconciled Cost Of Revenue
42.79
-7.23%
46.12
-17.47%
55.89
-8.22%
60.90
Gross Profit
42.54
-5.21%
44.88
-11.03%
50.45
+36.16%
37.05
Operating Expense
135.85
+3.00%
131.89
+16.21%
113.49
-18.74%
139.67
Research And Development
25.99
-9.86%
28.83
+11.11%
25.95
-30.59%
37.38
Selling General And Administration
109.86
+6.60%
103.06
+17.73%
87.54
-14.41%
102.28
Total Expenses
178.64
+0.35%
178.01
+5.10%
169.38
-15.55%
200.56
Operating Income
-93.31
-7.24%
-87.01
-38.02%
-63.04
+38.57%
-102.62
Total Operating Income As Reported
-110.25
+13.52%
-127.48
-66.43%
-76.60
+34.08%
-116.20
EBITDA
-85.70
-22.04%
-70.22
-28.95%
-54.46
+68.63%
-173.57
Normalized EBITDA
-68.75
-25.11%
-54.95
-34.38%
-40.90
+59.06%
-99.90
Reconciled Depreciation
10.98
-34.90%
16.86
+11.07%
15.18
+1.02%
15.03
EBIT
-96.68
-11.02%
-87.08
-25.05%
-69.64
+63.08%
-188.60
Total Unusual Items
-16.94
-10.99%
-15.27
-12.57%
-13.56
+81.59%
-73.67
Total Unusual Items Excluding Goodwill
-16.94
-10.99%
-15.27
-12.57%
-13.56
+81.59%
-73.67
Special Income Charges
-16.94
-10.99%
-15.27
-12.57%
-13.56
+0.21%
-13.59
Other Special Charges
Restructuring And Mergern Acquisition
16.94
+10.99%
15.27
+12.57%
13.56
-0.21%
13.59
Net Income
-74.90
+46.07%
-138.88
-86.03%
-74.66
+60.73%
-190.10
Pretax Income
-96.70
-6.97%
-90.40
-21.82%
-74.20
+61.54%
-192.93
Net Non Operating Interest Income Expense
9.15
-45.79%
16.88
+1579.90%
1.00
+147.74%
-2.10
Interest Expense Non Operating
0.03
-99.22%
3.32
-27.39%
4.57
+5.45%
4.33
Net Interest Income
9.15
-45.79%
16.88
+1579.90%
1.00
+147.74%
-2.10
Interest Expense
0.03
-99.22%
3.32
-27.39%
4.57
+5.45%
4.33
Interest Income Non Operating
9.18
-54.56%
20.20
+262.51%
5.57
+150.31%
2.23
Interest Income
9.18
-54.56%
20.20
+262.51%
5.57
+150.31%
2.23
Other Income Expense
-12.55
+38.10%
-20.27
-66.59%
-12.17
+86.20%
-88.21
Other Non Operating Income Expenses
4.39
+187.74%
-5.01
-460.03%
1.39
+109.57%
-14.54
Gain On Sale Of Security
-60.08
Tax Provision
-37.88
-7088.19%
0.54
+19.91%
0.45
+115.97%
-2.83
Tax Rate For Calcs
0.00
+86.67%
0.00
+0.00%
0.00
+1300.00%
0.00
Tax Effect Of Unusual Items
-6.64
-107.18%
-3.21
-12.57%
-2.85
-157.71%
-1.11
Net Income Including Noncontrolling Interests
-74.90
+46.07%
-138.88
-86.03%
-74.66
+60.73%
-190.10
Net Income From Continuing Operation Net Minority Interest
-58.83
+35.31%
-90.94
-21.81%
-74.66
+60.73%
-190.10
Net Income From Continuing And Discontinued Operation
-74.90
+46.07%
-138.88
-86.03%
-74.66
+60.73%
-190.10
Net Income Continuous Operations
-58.83
+35.31%
-90.94
-21.81%
-74.66
+60.73%
-190.10
Net Income Discontinuous Operations
-16.07
+66.48%
-47.95
0.00
Normalized Income
-48.52
+38.48%
-78.88
-23.36%
-63.94
+45.60%
-117.53
Net Income Common Stockholders
-74.90
+59.49%
-184.90
-147.67%
-74.66
+60.73%
-190.10
Diluted EPS
-0.20
+61.54%
-0.52
+44.68%
-0.94
+61.32%
-2.43
Basic EPS
-0.20
+61.54%
-0.52
+44.68%
-0.94
+61.32%
-2.43
Basic Average Shares
381.62
+8.21%
352.67
+345.52%
79.16
+1.09%
78.31
Diluted Average Shares
381.62
+8.21%
352.67
+345.52%
79.16
+1.09%
78.31
Diluted NI Availto Com Stockholders
-74.90
+59.49%
-184.90
-147.67%
-74.66
+60.73%
-190.10
Preferred Stock Dividends
46.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
567.75
-7.28%
612.35
+89.54%
323.07
-17.23%
390.31
Current Assets
454.26
+20.85%
375.88
+137.58%
158.22
-24.23%
208.81
Cash Cash Equivalents And Short Term Investments
187.57
-35.95%
292.87
+154.91%
114.89
-30.70%
165.78
Cash And Cash Equivalents
120.86
-27.51%
166.73
+222.47%
51.70
-36.41%
81.31
Cash Equivalents
53.89
Cash Financial
27.41
Other Short Term Investments
66.71
-47.12%
126.15
+99.63%
63.19
-25.20%
84.47
Receivables
13.43
-8.89%
14.74
-25.02%
19.66
+13.77%
17.28
Accounts Receivable
13.43
-8.89%
14.74
-25.02%
19.66
+13.77%
17.28
Gross Accounts Receivable
13.71
-8.57%
15.00
-24.89%
19.97
+11.75%
17.87
Allowance For Doubtful Accounts Receivable
-0.28
-9.23%
-0.26
+16.67%
-0.31
+47.30%
-0.59
Inventory
19.98
-3.68%
20.74
+1.03%
20.53
-4.38%
21.47
Raw Materials
8.63
-33.82%
13.04
+7.42%
12.14
-28.02%
16.87
Work In Process
0.25
-42.89%
0.44
+57.09%
0.28
-70.16%
0.94
Finished Goods
11.10
+52.85%
7.26
-10.49%
8.11
-46.80%
15.24
Prepaid Assets
Restricted Cash
0.00
Assets Held For Sale Current
228.41
+431.63%
42.96
Other Current Assets
4.87
+6.80%
4.56
+45.86%
3.13
-26.91%
4.28
Total Non Current Assets
113.49
-52.00%
236.46
+43.44%
164.85
-9.17%
181.50
Net PPE
46.01
-6.76%
49.34
-10.04%
54.85
-7.87%
59.53
Gross PPE
94.17
+5.09%
89.61
-0.81%
90.34
+2.00%
88.56
Accumulated Depreciation
-48.16
-19.61%
-40.27
-13.46%
-35.49
-22.25%
-29.03
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
43.50
Machinery Furniture Equipment
17.10
+117.66%
7.86
-1.70%
7.99
+6.50%
7.51
Construction In Progress
0.90
-85.07%
6.03
+158.27%
2.33
+44.79%
1.61
Other Properties
62.12
+0.23%
61.97
-6.42%
66.23
-1.47%
67.21
Leases
14.05
+2.19%
13.75
-0.26%
13.79
+12.68%
12.23
Goodwill And Other Intangible Assets
140.25
+30.20%
107.72
-9.37%
118.85
Goodwill
111.30
+4.68%
106.32
+0.06%
106.25
Other Intangible Assets
28.95
+1968.14%
1.40
-88.89%
12.60
Investments And Advances
25.70
0.00
Non Current Deferred Assets
38.63
+27891.30%
0.14
Non Current Deferred Taxes Assets
38.63
+27891.30%
0.14
Other Non Current Assets
3.15
-98.31%
186.98
+8083.02%
2.29
-26.50%
3.11
Total Liabilities Net Minority Interest
143.46
+2.02%
140.62
-70.15%
471.12
-0.14%
471.78
Current Liabilities
108.31
+64.36%
65.89
-39.73%
109.33
+151.66%
43.44
Payables And Accrued Expenses
16.10
+11.02%
14.50
-13.08%
16.69
-13.44%
19.28
Payables
5.41
+7.09%
5.05
-49.82%
10.06
+10.71%
9.09
Accounts Payable
5.41
+7.09%
5.05
-45.33%
9.24
+16.70%
7.91
Current Accrued Expenses
10.70
+13.13%
9.46
+42.70%
6.63
-34.97%
10.19
Pensionand Other Post Retirement Benefit Plans Current
18.15
+80.74%
10.04
-16.69%
12.05
+203.96%
3.96
Total Tax Payable
1.58
+91.64%
0.82
-29.73%
1.17
Current Debt And Capital Lease Obligation
5.49
+14.23%
4.81
-92.47%
63.85
+1007.60%
5.76
Current Debt
59.53
+2757.90%
2.08
Other Current Borrowings
59.53
+2757.90%
2.08
Current Capital Lease Obligation
5.49
+14.23%
4.81
+11.17%
4.32
+17.41%
3.68
Current Deferred Liabilities
42.94
+172.77%
15.74
-5.94%
16.73
+15.93%
14.44
Current Deferred Revenue
42.94
+172.77%
15.74
-5.94%
16.73
+15.93%
14.44
Other Current Liabilities
25.63
+23.21%
20.80
Total Non Current Liabilities Net Minority Interest
35.16
-52.96%
74.73
-79.34%
361.79
-15.54%
428.33
Liabilities Heldfor Sale Non Current
0.00
-100.00%
6.78
Long Term Debt And Capital Lease Obligation
25.34
-2.13%
25.89
-24.65%
34.36
-64.54%
96.89
Long Term Debt
0.30
+0.00%
0.30
-92.49%
3.98
-93.66%
62.81
Long Term Capital Lease Obligation
25.04
-2.16%
25.59
-15.75%
30.37
-10.88%
34.08
Non Current Deferred Liabilities
8.60
-79.02%
41.00
+171.22%
15.12
-21.39%
19.23
Non Current Deferred Revenue
7.79
-80.48%
39.92
+179.63%
14.28
-21.46%
18.18
Non Current Deferred Taxes Liabilities
0.81
-25.07%
1.08
+28.54%
0.84
-20.28%
1.05
Other Non Current Liabilities
1.22
+14.41%
1.06
-0.28%
1.06
+10.82%
0.96
Preferred Securities Outside Stock Equity
0.00
-100.00%
311.25
+0.00%
311.25
Stockholders Equity
424.29
-10.05%
471.72
+418.62%
-148.05
-81.73%
-81.47
Common Stock Equity
424.29
-10.05%
471.72
+418.62%
-148.05
-81.73%
-81.47
Capital Stock
0.40
+2.02%
0.40
+377.11%
0.08
+3.75%
0.08
Common Stock
0.40
+2.02%
0.40
+377.11%
0.08
+3.75%
0.08
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
404.96
+2.23%
396.11
+375.16%
83.36
+4.33%
79.90
Ordinary Shares Number
386.38
+2.34%
377.53
+370.55%
80.23
+0.94%
79.48
Treasury Shares Number
18.58
+0.00%
18.58
+493.23%
3.13
+642.18%
0.42
Additional Paid In Capital
1,732.39
+1.77%
1,702.22
+97.74%
860.82
+1.63%
847.01
Retained Earnings
-1,260.55
-6.32%
-1,185.65
-18.48%
-1,000.75
-8.06%
-926.10
Gains Losses Not Affecting Retained Earnings
-1.49
-221.80%
1.23
+155.16%
-2.22
-17.14%
-1.90
Treasury Stock
46.47
+0.00%
46.47
+677.43%
5.98
+961.63%
0.56
Other Equity Adjustments
-1.49
-221.80%
1.23
+155.16%
-2.22
-17.14%
-1.90
Total Equity Gross Minority Interest
424.29
-10.05%
471.72
+418.62%
-148.05
-81.73%
-81.47
Total Capitalization
424.59
-10.05%
472.02
+427.64%
-144.07
-672.15%
-18.66
Working Capital
345.96
+11.60%
309.99
+534.08%
48.89
-70.44%
165.37
Invested Capital
424.59
-10.05%
472.02
+658.35%
-84.54
-410.03%
-16.57
Total Debt
30.83
+0.43%
30.70
-68.75%
98.21
-4.33%
102.66
Net Debt
11.81
Capital Lease Obligations
30.53
+0.43%
30.40
-12.40%
34.70
-8.12%
37.76
Net Tangible Assets
424.29
-10.05%
471.72
+284.43%
-255.77
-27.68%
-200.32
Tangible Book Value
424.29
-10.05%
471.72
+284.43%
-255.77
-27.68%
-200.32
Interest Payable
4.26
0.00
Inventories Adjustments Allowances
-7.04
+39.21%
-11.58
Line Of Credit
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-74.34
+48.18%
-143.45
-231.40%
-43.29
+51.56%
-89.37
Cash Flow From Continuing Operating Activities
-74.34
+48.18%
-143.45
-231.40%
-43.29
+51.56%
-89.37
Net Income From Continuing Operations
-74.90
+46.07%
-138.88
-86.03%
-74.66
+60.73%
-190.10
Depreciation Amortization Depletion
10.98
-34.90%
16.86
+11.07%
15.18
+1.02%
15.03
Depreciation
9.26
-25.99%
12.52
+214.45%
3.98
+13.75%
3.50
Amortization Cash Flow
1.72
-60.54%
4.35
-61.20%
11.20
-2.85%
11.53
Depreciation And Amortization
10.98
-34.90%
16.86
+11.07%
15.18
+1.02%
15.03
Amortization Of Intangibles
1.72
-60.54%
4.35
-61.20%
11.20
-2.85%
11.53
Other Non Cash Items
3.75
+120.34%
-18.42
-483.55%
4.80
-1.78%
4.89
Stock Based Compensation
29.61
-6.68%
31.73
+141.80%
13.12
-11.81%
14.88
Provisionand Write Offof Assets
3.47
+37.40%
2.52
+68.72%
1.50
-81.00%
7.87
Asset Impairment Charge
0.00
0.00
-100.00%
3.53
Operating Gains Losses
-0.23
+63.29%
-0.63
73.80
Gain Loss On Investment Securities
-0.23
+63.29%
-0.63
60.08
Unrealized Gain Loss On Investment Securities
0.60
0.00
0.00
Gain Loss On Sale Of PPE
Change In Working Capital
-44.98
-54.05%
-29.20
-1380.58%
-1.97
+89.39%
-18.59
Change In Receivables
-39.45
-540.29%
8.96
+409.75%
-2.89
-372.15%
1.06
Changes In Account Receivables
-1.36
-115.18%
8.97
+399.80%
-2.99
-381.37%
1.06
Change In Inventory
-11.52
-16.65%
-9.88
-101.04%
-4.91
+41.98%
-8.47
Change In Prepaid Assets
1.14
+159.25%
-1.93
-323.78%
0.86
+2512.12%
0.03
Change In Payables And Accrued Expense
12.79
+205.21%
-12.16
-255.88%
7.80
+483.47%
1.34
Change In Accrued Expense
10.36
+1170.80%
0.81
-86.82%
6.18
+50.33%
4.11
Change In Payable
2.44
+118.78%
-12.97
-901.92%
1.62
+158.29%
-2.78
Change In Account Payable
2.44
+118.78%
-12.97
-901.92%
1.62
+158.29%
-2.78
Change In Other Working Capital
-1.31
+68.28%
-4.14
-568.67%
0.88
+125.50%
-3.47
Change In Other Current Liabilities
-6.62
+34.08%
-10.05
-170.66%
-3.71
+59.17%
-9.09
Investing Cash Flow
27.41
-92.45%
363.17
+1694.60%
20.24
+122.96%
-88.13
Cash Flow From Continuing Investing Activities
27.41
-92.45%
363.17
+1694.60%
20.24
+122.96%
-88.13
Net PPE Purchase And Sale
-8.30
+0.62%
-8.36
-195.13%
-2.83
+25.99%
-3.83
Purchase Of PPE
-8.30
+0.62%
-8.36
-195.13%
-2.83
+25.99%
-3.83
Capital Expenditure
-8.30
+0.62%
-8.36
-195.13%
-2.83
+25.99%
-3.83
Net Investment Purchase And Sale
40.71
-56.17%
92.88
+302.64%
23.07
+127.36%
-84.30
Purchase Of Investment
-138.29
+46.01%
-256.12
-169.89%
-94.90
+30.89%
-137.30
Sale Of Investment
179.00
-48.71%
349.00
+195.85%
117.96
+122.57%
53.00
Net Business Purchase And Sale
0.00
-100.00%
278.65
0.00
0.00
Purchase Of Business
0.00
+100.00%
-1.39
0.00
0.00
Gain Loss On Sale Of Business
0.00
-100.00%
13.72
Net Other Investing Changes
-5.00
Financing Cash Flow
0.57
+100.56%
-102.62
-1407.06%
-6.81
-102.95%
230.76
Cash Flow From Continuing Financing Activities
0.57
+100.56%
-102.62
-1407.06%
-6.81
-102.95%
230.76
Net Issuance Payments Of Debt
0.00
+100.00%
-63.19
-2933.70%
-2.08
-111.47%
18.16
Issuance Of Debt
0.00
0.00
-100.00%
25.00
Repayment Of Debt
0.00
+100.00%
-63.19
-2933.70%
-2.08
+69.54%
-6.84
Long Term Debt Issuance
0.00
0.00
-100.00%
25.00
Long Term Debt Payments
0.00
Net Long Term Debt Issuance
0.00
0.00
-100.00%
25.00
Short Term Debt Issuance
0.00
Short Term Debt Payments
0.00
+100.00%
-63.19
-2933.70%
-2.08
+69.54%
-6.84
Net Short Term Debt Issuance
0.00
+100.00%
-63.19
-2933.70%
-2.08
+69.54%
-6.84
Net Common Stock Issuance
0.00
+100.00%
-40.49
-647.88%
-5.41
-861.63%
-0.56
Common Stock Payments
0.00
+100.00%
-40.49
-647.88%
-5.41
-861.63%
-0.56
Repurchase Of Capital Stock
0.00
+100.00%
-40.49
-647.88%
-5.41
-861.63%
-0.56
Proceeds From Stock Option Exercised
1.05
-49.08%
2.07
+150.30%
0.83
-9.81%
0.92
Net Other Financing Charges
-0.48
+51.79%
-1.00
-622.30%
-0.14
+98.91%
-12.76
Changes In Cash
-46.36
-139.59%
117.10
+492.19%
-29.86
-156.06%
53.26
Effect Of Exchange Rate Changes
0.84
+207.26%
-0.79
-2408.82%
0.03
+108.42%
-0.40
Beginning Cash Position
168.82
+221.56%
52.50
-36.23%
82.32
+179.38%
29.47
End Cash Position
123.30
-26.97%
168.82
+221.56%
52.50
-36.23%
82.32
Free Cash Flow
-82.65
+45.56%
-151.81
-229.18%
-46.12
+50.51%
-93.19
Interest Paid Supplemental Data
0.01
-99.51%
3.09
-19.14%
3.82
+9.33%
3.49
Income Tax Paid Supplemental Data
0.61
-24.22%
0.80
+159.22%
0.31
Amortization Of Securities
-2.64
+64.44%
-7.43
-489.61%
-1.26
-87.09%
-0.67
Common Stock Issuance
Issuance Of Capital Stock
0.00
0.00
-100.00%
225.00
Net Preferred Stock Issuance
0.00
0.00
-100.00%
225.00
Preferred Stock Issuance
0.00
0.00
-100.00%
225.00
Sale Of Business
0.00
-100.00%
280.03
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category